期刊文献+

曲格列汀琥珀酸盐晶体结构和晶型稳定性研究 被引量:3

Crystal structure and crystal form stability of trelagliptin succinate
原文传递
导出
摘要 采用重结晶方法和混悬方法研究曲格列汀琥珀酸盐在极性溶剂(水和95%乙醇)中的转晶情况。采用X射线单晶衍射、X射线多晶衍射和热分析等多种分析方法,对曲格列汀琥珀酸盐转晶前后的结晶形式进行了结构表征。结果表明,曲格列汀琥珀酸盐在溶剂介导下特别是极性溶剂介导下容易转化成曲格列汀半琥珀酸盐。 In order to investigate trelagliptin succinate's stability in solution, recrystallization and suspension methods in polar solvent (mainly in water and 95% alcohol) were used to study the crystal form transformation of trelagliptin succinate. Single crystal X-ray diffraction, powder X-ray diffraction and thermalgravimetric analysis, and differential scanning calorimetry were used to characterize the structure of the solid state form before and after transformation. The results showed that trelagliptin succinate can easily convert to trelagliptin hemi-succinate mediated by solvent, especially by polar solvent, namely trelagliptin hemi-succinate is more stable than trelagliptin succinate in solution.
出处 《药学学报》 CAS CSCD 北大核心 2016年第11期1759-1764,共6页 Acta Pharmaceutica Sinica
关键词 曲格列汀半琥珀酸盐 曲格列汀琥珀酸盐 晶体结构 稳定性 转晶 trelagliptin hemi-succinate trelagliptin succinate crystal structure stability transformation
  • 相关文献

参考文献4

二级参考文献48

  • 1黄建权,傅得兴,胡欣,张君仁.抗糖尿病药物维达列汀[J].中国新药杂志,2007,16(6):486-488. 被引量:11
  • 2KODA-KIMBLE MA著,王秀兰,张淑文译.临床药物治疗学[M].第8版.北京:人民卫生出版社,2007:50:3-4. 被引量:1
  • 3THORNBERRY NA, WEBER AE. Discovery of JANUVIA (Sitagliptin) , a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [ J ]. Curr Top Med Chem, 2007, 7 (6) : 557 -568. 被引量:1
  • 4HAVALE SH, PAL M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes [ J ]. Bioorg Med Chem, 2009, 17 ( 5 ) : 1783 - 1802. 被引量:1
  • 5EDMONDSON SD, MASTRACCHIO A, DUFFY JL, et al. Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors [ J ].Bioorg Med Chem Lett, 2005, 15(12) : 3048 -3052. 被引量:1
  • 6DEACON CF. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes [ J ]. Curr Opin lnvestig Drugs, 2008, 9(4) : 402 -413. 被引量:1
  • 7AUGERI DJ, ROBL JA, BETEBENNER DA, et al. Discovery and preclinical profile of Saxagliptin (BMS-477118) : a highly potent, long-acting, orally active dipeptidyl peptidase Ⅳ inhibitor for the treatment of type 2 diabetes[ J]. J Med Chem, 2005, 48(15) : 5025 -5037. 被引量:1
  • 8BRAZG R, THOMAS K, ZHAO P, et al. Effect of adding MK- 0431 to on-going metformin therapy in type 2 diabetic patients who have inadequate glycemic control on metformin [ J]. Diabetes, 2005, 54(Suppl 1):A3. 被引量:1
  • 9CHARBONNEL B, KARASIK A. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 dabetes inadequately controlled with metformin alone [ J ]. Diabetes Care, 2006, 29 (12) : 2638 - 2643. 被引量:1
  • 10NAUCK M, MEINININGER G, SHENG D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared to the sulphonylurea glipizidein patients with type 2 diabetes inadequately controlled on mefformin alone: a randomized, double-blind, non-inferiority trial [ J ]. Diabetes Obes Metab, 2007, 9(2) :194 -205. 被引量:1

共引文献58

同被引文献23

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部